Abbratech contracts with customers to develop therapeutic, diagnostic, and research antibodies that target sites on proteins at a precision not currently achievable using novel immunization and in vitro display methodologies. Researchers are not limited to ‘a good epitope’ or need worry about tolerance preventing the isolation of a much-needed affinity molecule to a specific site on a protein. Abbratech generates antibodies to precise sites with single amino acid precision. Therapeutic and diagnostic antibodies are identified, cloned and developed in a high-throughput, efficient manner superior to standard antibody production.